Advertisement

India

Updated on: Wednesday, June 02, 2021, 01:27 AM IST

Treating Covid-19: Lilly India gets nod for use of monoclonal antibody drugs

COVID-19 Vaccination  | AFP

COVID-19 Vaccination | AFP

Advertisement

New Delhi

Eli Lilly and Company India said on Tuesday it has received permission for restricted emergency use of its antibody drugs bamlanivimab 700 mg and etesevimab 1,400 mg in India for treatment of patients with mild to moderate Covid-19.

Both drugs together are indicated for restricted use in emergency situation, IV route for the treatment of mild to moderate Covid-19 for injection administration in hospital settings in adults and pediatric patients.

Lilly said it is engaging in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab to speed up access and provide treatment options for patients with Covid-19.

The drugs together have been authorised under emergency use authorisation in the US and select European Union countries.

Antibody cocktail treatment begins at Delhi’s Ganga Ram

The Sir Ganga Ram Hospital on Tuesday started admini­st­e­r­ing monoclonal anti­body cocktail (MAC) to corona­virus patients, the medical faci­lity said. It is administering a combination of casirivimab and imdevimab to consenting patie­nts with mild and moderate Covid-19 symptoms at high risk of developing serious illness, it added. The MRP of one MAC dose for a patient is Rs59,750, the statement said.The Sir Ganga Ram Hospital on Tuesday started admini­st­e­r­ing monoclonal anti­body cocktail (MAC) to corona­virus patients, the medical faci­lity said. It is administering a combination of casirivimab and imdevimab to consenting patie­nts with mild and moderate Covid-19 symptoms at high risk of developing serious illness, it added. The MRP of one MAC dose for a patient is Rs59,750, the statement said.

Biological E ties up with Canada’s Providence to produce mRNA vaccine

Hyderabad: Biological E Limited has tied up with Canada’s Provi­de­nce Therapeutics to locally manufacture its mRNA corona­virus vaccine, the Hyderabad-bas­ed firm said on Tuesday, adding it will run a pivotal trial in India, and seek emergency-use authori­sation. As per Biological E, the term sheet sets forth the material terms for a definitive licensing and collaboration agreement and also outlines the terms for sale by Providence of up to 30 million doses of Providence’s proprietary messenger RNA vaccine, PTX-COVID19-B, to Biological E and other end-buyers.

Biological E Limited will run a pivotal trial in India and seek EUA, it added.

Advertisement

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Published on: Wednesday, June 02, 2021, 01:27 AM IST
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement